Clinical Trials Browser

Completed × INDUSTRY × Lenalidomide × Clear all

NCT03601078 2026-03-04

KarMMa-2

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

737 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT03934684 2025-08-06

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Phase 4 Completed

101 enrolled 11 charts

Multiple Myeloma

NCT01711671 2025-08-03

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Multiple Myeloma, Recurrence

NCT01996865 2025-07-10

MAGNIFY

Phase 3 Completed

503 enrolled 18 charts 1 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04436107 2025-05-23

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Completed

66 enrolled 52 charts

Lymphoma, Large B-Cell, Diffuse

NCT01476787 2025-05-14

RELEVANCE

Phase 3 Completed

1,030 enrolled 12 charts

Lymphoma, Follicular

NCT00179673 2025-05-13

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Phase 2 Completed

43 enrolled 16 charts

Lymphoma, Non-Hodgkin

NCT02076009 2025-05-01

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

569 enrolled 18 charts

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 2 FDA

Multiple Myeloma

NCT03098589 2025-03-30

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Head & NeckLymphoidOther hematologic neoplasm

Sleepiness, Arrhythmias, Cardiac, Cataract, Confusion, Coronary Artery Disease, Digestive System Diseases, Dizziness, Fatigue, Heart Failure, Hemorrhage, Hypersensitivity, Hypotension, Orthostatic, Hypothyroidism, Infections, Lymphoma, Peripheral Nervous System Diseases, Seizures, Thromboembolism, Tumor Lysis Syndrome, Neoplasms, Second Primary, Lung Diseases, Interstitial, Renal Insufficiency, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Teratogenesis

NCT03544281 2025-03-18

DREAMM 6

Phase 1/2 Completed

153 enrolled 91 charts

Multiple Myeloma

NCT04036448 2025-03-11

RevlimidPMS

LymphoidMyeloid

Lymphoma, Follicular, Myelodysplastic Syndromes, Recurrence, Lymphoma, Mantle-Cell

NCT03647124 2025-03-04

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Recurrence, Lymphoma, Mantle-Cell

NCT02918331 2025-02-03

A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

Phase 1 Completed

Multiple Myeloma

NCT04134936 2024-10-16

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Phase 1 Completed

66 enrolled 21 charts

Lymphoma, Large B-Cell, Diffuse

NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Phase 1/2 Completed

20 enrolled 9 charts

GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

NCT03859427 2024-08-13

ARROW2

Phase 3 Completed

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT03952091 2024-07-03

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

Multiple Myeloma

NCT02513186 2024-01-29

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Phase 1 Completed

Multiple Myeloma

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

Multiple Myeloma, Recurrence

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02685826 2023-10-06

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Phase 1/2 Completed

56 enrolled 38 charts

Multiple Myeloma

NCT04196491 2023-08-23

KarMMa-4

Phase 1 Completed

Multiple Myeloma

NCT01749969 2023-07-13

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

Phase 1 Completed

Multiple Myeloma

NCT01348919 2023-06-28

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

11 enrolled 15 charts

Multiple Myeloma, Neoplasms

NCT02285062 2023-06-22

ROBUST

Phase 3 Completed

570 enrolled 27 charts

Limb-girdle muscular dystrophy, type 2C, Lymphoma, Large B-Cell, Diffuse

NCT01564537 2023-03-10

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 3 Completed

722 enrolled 29 charts

Multiple Myeloma

NCT01938001 2023-02-22

AUGMENT

Phase 3 Completed

358 enrolled 18 charts 1 FDA

Lymphoma, Non-Hodgkin

NCT01335399 2022-09-30

ELOQUENT - 1

Phase 3 Completed

748 enrolled 15 charts

Multiple Myeloma

NCT02272803 2022-06-22

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

Phase 2 Completed

82 enrolled 13 charts

Multiple Myeloma

NCT01239797 2022-06-01

ELOQUENT - 2

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT02631577 2022-04-13

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 1/2 Completed

38 enrolled 20 charts

Lymphoma, Follicular

NCT01583283 2022-02-23

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence

NCT02077166 2022-02-04

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

138 enrolled 22 charts

Lymphoma, Large B-Cell, Diffuse

NCT00774345 2021-12-02

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

Phase 3 Completed

317 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01421186 2021-11-16

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

91 enrolled 19 charts

Multiple Myeloma

NCT01953692 2021-08-04

MK-3475-013

Phase 1 Completed

197 enrolled 52 charts

LymphoidMyeloidPlasma cell

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse

NCT02112175 2021-04-14

ARUMM

Phase 3 Completed

Multiple Myeloma

NCT02431208 2021-04-02

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Phase 1 Completed

Multiple Myeloma

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

241 enrolled 31 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT00532675 2020-12-19

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00642954 2020-11-18

MK-0683-074

Phase 1 Completed

31 enrolled 13 charts

Multiple Myeloma, Recurrence

NCT02335983 2020-11-06

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Phase 1 Completed

107 enrolled 25 charts

Multiple Myeloma

NCT02538965 2020-01-07

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Completed

17 enrolled 21 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

NCT01732861 2019-12-20

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00622336 2019-11-20

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Phase 3 Completed

330 enrolled 10 charts

Multiple Myeloma